Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR)

Liraglutide, a glucagon-like peptide 1 (GLP1) receptor agonist, is known to inhibit the atherosclerosis of apoE mice and suppress the cellular behaviors of VSMCs induced by AngII. This study aimed to explore whether liraglutide can reduce the proliferation, invasion and phenotypic transformation of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioengineered 2021-01, Vol.12 (1), p.8057-8066
Hauptverfasser:	Ji, Jingquan, Feng, Ming, Niu, Xiaohong, Zhang, Xinyu, Wang, Yilei
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biotechnology & Applied Microbiology Cell Movement - drug effects Cell Proliferation - drug effects Cells, Cultured Down-Regulation Gene Expression Regulation - drug effects Homocysteine - pharmacology Humans LDLR Life Sciences & Biomedicine Liraglutide Liraglutide - pharmacology Mice migration Muscle, Smooth, Vascular - cytology Muscle, Smooth, Vascular - drug effects PCSK9 Phenotype proliferation Proprotein Convertase 9 - metabolism Receptors, LDL - metabolism Research Paper Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!